StreetInsider.com News Articles

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Stifel Reiterates Buy Rating on Arrowhead Pharma (ARWR)

Mon, 31 Aug 2026 09:21:09 -0400

Stifel analyst James Condulis reiterated a Buy rating and $104.00 price target on Arrowhead Pharma (NASDAQ: ARWR).

The analyst commented, "Detailed SHASTA results are favorable and arguably support a best-in-class profile. Investors generally expected these data to look good, but the details here are still important--especially as it relates to safety (liver enzymes/fat, platelets, hypersensitivity/ISRs, etc. in aggregate do look better vs. olezarsen) as we think that safety+dosing are really the key differentiators here (both plozasiran/olezarsen look highly/similarly efficacious). For the stock, attention should shift to the Tryngolza launch and what it may imply for the TAM--early commentary from IONS is

RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR)

Mon, 31 Aug 2026 08:40:28 -0400

RBC Capital analyst Luca Issi reiterated an Outperform rating and $100.00 price target on Arrowhead Pharma (NASDAQ: ARWR).

The analyst commented: "ARWR Delivers Solid Data At ESC And Dinner With C-suite Highlights Commercial Readiness; ARWR presented full Phase III data for sHTG at the European Society of Cardiology Congress, and we had an opportunity to host the Csuite for dinner right after the presentation. On efficacy, ARWR highlighted an impressive benefit in trigs (52-55% reaching trigs <150 mg/dL vs 2-8% placebo), acute pancreatitis (78% reduction for ITT and 91% for higher risk patients) and the team believes that trig reduction seen

Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data

Sun, 30 Aug 2026 11:30:19 -0400

Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented detailed results from its Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 in Munich, Germany.

Both studies met their primary and all prespecified secondary endpoints. In a pooled analysis, plozasiran reduced cumulative acute pancreatitis (AP) events by 78% versus placebo among patients with triglyceride (TG) levels above 500 mg/dL, corresponding to a 4.1% absolute risk reduction and a number needed to treat of 24 over one year. Among patients with TG levels above 500 mg/dL and a prior history of AP, the

Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data

Sun, 30 Aug 2026 11:30:19 -0400

Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data

Sun, 30 Aug 2026 11:30:19 -0400

Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data

Sun, 30 Aug 2026 11:30:19 -0400

Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data

Sun, 30 Aug 2026 11:30:19 -0400

Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data

Sun, 30 Aug 2026 11:30:19 -0400

Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data

Sun, 30 Aug 2026 11:30:19 -0400

Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data

Sun, 30 Aug 2026 11:30:19 -0400

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

Sun, 30 Aug 2026 11:30:00 -0400

- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population -

- More than 90% of plozasiran-treated patients achieved triglycerides below thresholds for AP risk, 500 mg/dL at Month 12, and more than half achieved triglycerides below 150 mg/dL -

- Plozasiran reduced cumulative acute pancreatitis (AP) events by 78% versus placebo in patients with TG above 500 mg/dL, with or without a prior history of AP -

- Greater absolute benefit of AP risk reduction was observed in patients at higher risk -

- In the highest-risk subgroup,